UT MD Anderson CCOP Research Base

UT MD 安德森 CCOP 研究基地

• 批准号: 7118029
• 负责人: MICHAEL Jordan FISCH
• 金额: $ 10.57万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7118029
• 关键词: behavioral medicine; cancer complication; cancer prevention; cancer risk; chemoprevention; clinical research; clinical trial phase III; community health services; cooperative study; data management; female reproductive system neoplasm; health services research tag; human subject; human therapy evaluation; medical outreach /case finding; neoplasm /cancer; neoplasm /cancer chemotherapy; neoplasm /cancer education; neoplasm /cancer palliative treatment; neoplasm /cancer relapse /recurrence; neoplasm /cancer therapy; outcomes research; patient oriented research

DESCRIPTION (provided by applicant): Since the awarding of its first NCI Grant in 1987, the University of Texas M.D. Anderson Cancer Center Community Clinical Oncology Program (MDACCOP) Research Base has managed 150 clinical trials involving more than 5,000 patients, including 2,688 patients entered onto chemoprevention trials. The MDACCOP Research Base will continue to generate and support a spectrum of clinical studies of cancer control, prevention and therapy that can be implemented and conducted efficiently in a community environment. The Research Base and its affiliated CCOP sites have the full support and institutional resources, including the clinical research infrastructure, of the MDACC, the world?s largest and highest ranked comprehensive cancer center. The following specific aims are proposed: 1. Provide affiliate CCOPs and MBCCOPs access to MDACC clinical trials. 2. Transfer information, technology, and standards from the academic centers to the community. 3. Enhance the development of prevention and control trials that include behavioral interventions, chemoprevention trials, symptom control, the identification of individuals at increased risk for cancer or recurrence of their cancer, and the development of health outcomes research in the community setting. 4. Integrate the Gynecology Oncology Group (GOG) CCOPs into the MDACCOP RB; enable the current MDACCOPs to access the GOG studies and affiliate with another RB (as a 5th affiliate). 5. Develop new methodologies for answering cancer control questions in a multi-institutional setting, such as remote symptom assessment, and establish the educational support systems for initiation of these studies in the community. 6. Provide strategies to increase the recruitment of members of minority groups and women for clinical and cancer control trials. 7. Maintain a comprehensive data management system that links MDACC to the affiliate CCOPs and MBCCOPs. This system ensures the accurate collection and transmission of information for research trials and provides a facility to enhance ongoing quality assurance, data monitoring, and on-site audits. 8. Work with the NCI Community Oncology and Prevention Trials Research Group to ensure the research programs of the RB are congruent with the goals of the national program.

描述（由申请人提供）：自授予第一个 NCI 以来 1987 年获得德克萨斯大学 M.D. 安德森癌症中心社区资助 临床肿瘤学计划（MDACCOP）研究基地已管理150个临床 试验涉及 5,000 多名患者，其中 2,688 名患者入组 进行化学预防试验。 MDACCOP研究基地将继续 产生并支持一系列癌症控制的临床研究， 可以在一定范围内有效实施和进行的预防和治疗 社区环境。研究基地及其附属的CCOP站点有 全力支持和机构资源，包括临床研究 MDACC 的基础设施是世界上最大且排名最高的 综合癌症中心。提出以下具体目标： 1. 向附属 CCOP 和 MBCCOP 提供 MDACC 临床试验的访问权限。 2. 从学术中心转移信息、技术和标准 到社区。 3. 加强防控试验的开展，包括 行为干预、化学预防试验、症状控制、 识别癌症或复发风险增加的个体 他们的癌症以及社区健康结果研究的发展 环境。 4. 将妇科肿瘤学组 (GOG) CCOP 纳入 MDACCOP RB； 使当前的 MDACCOP 能够访问 GOG 研究并加入 另一个 RB（作为第五个附属机构）。 5. 开发新的方法来回答癌症控制问题 多机构设置，例如远程症状评估，并建立 启动这些研究的教育支持系统 社区。 6. 提供增加少数民族成员招募的策略 团体和妇女进行临床和癌症控制试验。 7. 维护一个将 MDACC 与 附属 CCOP 和 MBCCOP。该系统保证了准确的采集和 传输研究试验信息并提供设施 加强持续的质量保证、数据监控和现场审核。 8. 与 NCI 社区肿瘤​​学和预防试验研究小组合作 确保 RB 的研究计划与 RB 的目标一致 国家计划。